-
2023-509516-28-00
4
2021-02-22
Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
-
2022-503072-84-00
5
2021-02-13
stage IIIa cardiac AL amyloidosis
-
2022-503073-11-00
5
2021-02-13
Stage IIIb cardiac AL amyloidosis
-
2023-507475-21-00
10
2021-01-18
Lung Cancer, Non-Small Cell
-
2024-512232-30-00
10
2021-01-18
Primary Biliary Cholangitis
-
2024-513730-38-00
5
2021-01-13
Resectable Non-small cell lung cancer
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2022-501645-70-00
5
2020-11-25
Crohns Disease
-
2023-506515-18-00
5
2020-10-23
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-506576-27-00
5
2020-09-30
EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2023-505830-89-00
6
2020-08-05
metastatic castrate resistant prostate cancer (mCRPC)
-
2023-509089-39-00
5
2020-07-01
Non-Muscle Invasive Bladder Cancer
-
2024-515669-32-00
5
2020-06-30
Pulmonary arterial hypertension
-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-505042-25-00
5
2020-05-05
Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
-
2024-511317-38-00
4
2020-05-04
ALK+ non-small cell lung cancer
-
2024-516532-97-00
9
2020-03-26
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
-
2023-506783-14-00
5
2020-02-24
Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
-
2024-511653-22-00
5
2020-02-12
Cutaneous Squamous Cell Carcinoma (CSCC)
-
2023-508635-31-00
5
2019-12-03
Hepatocellular Carcinoma
-
2024-510626-89-00
5
2019-11-18
Non-Alcoholic Steatohepatitis (NASH)
-
2022-502658-15-00
5
2019-09-22
Resectable Stage II-IIIB Non-small cell lung cancer